Wedbush Expects Reduced Earnings for Oruka Therapeutics

Oruka Therapeutics, Inc. (NASDAQ:ORKA) – Equities researchers at Wedbush decreased their FY2024 earnings estimates for shares of Oruka Therapeutics in a research report issued to clients and investors on Wednesday, November 13th. Wedbush analyst D. Nierengarten now anticipates that the company will earn ($2.46) per share for the year, down from their previous forecast of ($0.99). Wedbush has a “Strong-Buy” rating on the stock. The consensus estimate for Oruka Therapeutics’ current full-year earnings is ($2.50) per share. Wedbush also issued estimates for Oruka Therapeutics’ Q4 2024 earnings at ($0.36) EPS, Q1 2025 earnings at ($0.40) EPS, Q2 2025 earnings at ($0.44) EPS, Q3 2025 earnings at ($0.45) EPS, Q4 2025 earnings at ($0.46) EPS, FY2025 earnings at ($1.74) EPS, FY2026 earnings at ($2.08) EPS, FY2027 earnings at ($2.45) EPS and FY2028 earnings at ($2.94) EPS.

Several other equities research analysts have also issued reports on ORKA. Jefferies Financial Group started coverage on shares of Oruka Therapeutics in a report on Friday, September 13th. They issued a “buy” rating and a $40.00 price target on the stock. Leerink Partners started coverage on shares of Oruka Therapeutics in a report on Tuesday, September 17th. They issued an “outperform” rating and a $44.00 price target on the stock. Lifesci Capital started coverage on shares of Oruka Therapeutics in a report on Monday, September 16th. They issued an “outperform” rating and a $41.00 price target on the stock. TD Cowen started coverage on shares of Oruka Therapeutics in a report on Monday, September 16th. They issued a “buy” rating on the stock. Finally, HC Wainwright reissued a “buy” rating and issued a $45.00 price target on shares of Oruka Therapeutics in a report on Thursday, October 31st. Six equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $43.17.

Oruka Therapeutics Trading Up 0.2 %

NASDAQ:ORKA opened at $24.04 on Monday. The firm has a market cap of $29.09 million, a PE ratio of -3.84 and a beta of 0.87. Oruka Therapeutics has a one year low of $18.72 and a one year high of $53.88. The firm’s fifty day moving average is $26.76.

Institutional Investors Weigh In On Oruka Therapeutics

Several large investors have recently made changes to their positions in ORKA. Geode Capital Management LLC bought a new stake in shares of Oruka Therapeutics in the 3rd quarter worth about $343,000. The Manufacturers Life Insurance Company bought a new stake in shares of Oruka Therapeutics in the 3rd quarter worth about $1,037,000. Wellington Management Group LLP bought a new stake in shares of Oruka Therapeutics in the 3rd quarter worth about $2,013,000. Janus Henderson Group PLC bought a new stake in shares of Oruka Therapeutics in the 3rd quarter worth about $5,840,000. Finally, Redmile Group LLC bought a new stake in shares of Oruka Therapeutics in the 3rd quarter worth about $10,091,000. Institutional investors own 56.44% of the company’s stock.

Oruka Therapeutics Company Profile

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.